WHITE MATTER LESIONS IN FTLD: DISTINCT PHENOTYPES CHARACTERIZE GRN AND C9ORF72 MUTATIONS

Frontotemporal lobar degeneration (FTLD) has a high frequency of genetic forms; the 2 most common are GRN (progranulin) and C9ORF72 mutations. Recently, our group reported extensive white matter (WM) lesions in 4 patients with FTLD caused by GRN mutation, in the absence of noteworthy cardiovascular risk factors,1 in line with other studies in GRN mutation carriers.2,3 Here we compared the characteristics of frontal WM lesions in patients with behavioral variant of FTLD (bv-FTLD) caused by GRN and C9ORF72 mutations.

Methods. Patients. We retrospectively collected clinical and MRI data from 28 patients with a diagnosis of bv-FTLD based on the Rasovsky criteria,4 including 11 GRN mutation carriers and 17 C9ORF72 mutation carriers. One patient with multiple cardiovascular risk factors was excluded from this study; all other patients had no cardiovascular risk factors apart from sex, age, or treated and well-controlled hypertension. Age at onset was determined as the time of symptom appearance reported by the closest relative of the patient. A group of 11 age-matched healthy individuals were used as controls. Two GRN patients have been reported in a previous publication.1 This retrospective study was approved by our institutional review board. Informed consent was obtained according to the French legislation for clinical genetic studies.

MRI. All patients had a brain MRI including fluid-attenuated inversion recovery (FLAIR) sequence (1.5T/3T, echo time >100 ms, slice thickness ≤5 mm). One neuroradiologist (F.A.) assessed the severity of left and right frontal atrophy using the Kipps-Davis scale for frontal atrophy.5 Three neuroradiologists (F.A., S.S., and A. Bertrand) and 1 neurologist (P.C.) characterized the severity of WM lesions on FLAIR images in the left and right frontal lobes using an ad hoc 3-level visual score (figure). All readers were blinded to clinical and genetic data.

Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). Interrater agreements were assessed using the weighted κ test. Comparisons of sex and symptoms between the 3 groups were assessed using the χ² test; other comparisons were assessed using the Kruskal-Wallis test and Dunn post hoc test (when comparing 3 groups) or the Mann-Whitney test (when comparing 2 groups).

Results. No significant difference was observed between groups regarding sex, age at onset, age at MRI, disease duration, and associated amyotrophic lateral sclerosis symptoms (table e-1 at Neurology.org/ng).

Interrater agreement between the 4 readers for the characterization of WM lesions was moderate to very strong (κ = 0.536–0.805, median 0.74).

Frontal WM lesions were different between the 3 groups (p = 0.007 for the right side and p < 0.0001 for the left side, Kruskal-Wallis test). The grade of WM lesions was higher on both sides in the GRN group than in the control group and the C9ORF72 group (Dunn post hoc test) (figure).

In GRN mutation carriers, the presence of grade C WM lesions on the left side was associated with a higher degree of left frontal atrophy (p = 0.003, Mann-Whitney test) but not with longer disease duration (p = 0.082, Mann-Whitney test). No significant result was observed for the right side, where WM lesions were less frequent.

Discussion. Previous reports have shown that some FTLD cases with GRN mutation present with marked FLAIR hyperintensities in the WM.1–3,6 Here we extended these findings by showing that these WM lesions are frequent: 45% (5/11) of GRN mutation carriers had extensive frontal WM lesions (grade C) in the absence of noteworthy cardiovascular risk factors. These WM lesions were atypical for common cerebral small vessel disease because they extended toward the subcortical WM (figure) and were associated with a higher degree of left frontal atrophy. They were not associated with longer disease duration; thus, they may be a consequence of a faster atrophy process than in the other patients. Of note, the patient excluded from the study because of cardiovascular risk factors had only grade A WM lesions in the frontal lobes.

It is interesting that both GRN and C9ORF72 mutation carriers are likely to have underlying FTLD-TDP43 pathology. This suggests that gene effects can exceed lesion effects in the phenotypical expression of
FTLD. The progranulin protein is normally expressed not only in neurons but also in activated microglia, astrocytes, and oligodendroglia and plays a role in inflammation. Histopathologic studies of the WM in GRN mutation carriers have reported microglial activation in the areas of abnormal WM on MRI. These results favor the hypothesis of a specific vulnerability of the WM to granulin haploinsufficiency.


Author contributions: Study concept and design: F. Ameur, A. Bertrand, O. Colliot, and I. Le Ber. Acquisition of data: F. Ameur, A. Bertrand, P. Caroppo, and I. Le Ber. Analysis and interpretation of data: F. Ameur, A. Bertrand, P. Caroppo, S. Ströer, O. Colliot, and I. Le Ber. Drafting of the manuscript: F. Ameur and A. Bertrand. Critical revision of the manuscript for important intellectual content: P. Caroppo, D. Dormont, A. Brice, I. Le Ber, O. Colliot, C. Aznar, and B. Dubois.

Study funding: This work was supported by the program "Investissements d’avenir," grant ANR-10-IAIHU-06; by the PHRC FTLD-exome, grant NCT02363062 (to I.L.B.); by the Association PSP-France (to I.L.B.); by the France Alzheimer Association, grant R12091DD (to A. Brice); by Neuromics FP7, grant E120093DD (to A. Brice); by the Roger de Spoelberch Foundation, grant R12123DD (to A. Brice); by the PHRC Predict PGRN, grant AOM08045 (to A. Brice); and by the Fondation Plan Alzheimer (to A. Brice). Dr. Paola Caroppo received a PhD Fellowship from Carlo Besta Institute, Milan, Italy.

Disclosure: Dr. Ameur reports no disclosures. Dr. Colliot has received lecture fees from Roche; has served on the editorial board of Medical Image Analysis (Elsevier); and has received research support from Agence Nationale de la Recherche and Fondation Plan Alzheimer.
Dr. Caroppo reports no disclosures. Mr. Ströer has received research support from the Société Française de Radiologie. Dr. Dormont has received travel funding from Guerbet Group France; has served on the editorial board of the American Journal of Neuroradiology; holds a patent as Co-inventor of the Neurinfarct software, which is protected by an international patent (WO 2008/000973) currently owned by Intelligence in Medical Technologies, Paris; and has been a consultant for Medtronic, France. Dr. Brice has received honoraria from Lundbeck and has received research support from “Investissements d’avenir” and the France Parkinson Association. Dr. Azuar reports no disclosures. Dr. Dubois has been a consultant for Els Lilly and has received research support from INSERM, ANR, and PHRC. Dr. Le Ber reports no disclosures. Dr. Bertrand has received research support from IHU-a-ICM. Go to Neurology.org/ng for full disclosure forms.

Received June 17, 2015. Accepted in final form November 19, 2015.

Correspondence to Dr. Bertrand: anne.bertrand@aphp.fr


© 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
White matter lesions in FTLD: distinct phenotypes characterize GRN and C9ORF72 mutations
Fatima Ameur, Olivier Colliot, Paola Caroppo, et al.
Neurol Genet 2016;2:
DOI 10.1212/NXG.0000000000000047

This information is current as of January 28, 2016